Management of hepatitis C in patients with chronic kidney disease

被引:0
|
作者
Roberto J Carvalho-Filho [1 ]
Ana Cristina CA Feldner [1 ]
Antonio Eduardo B Silva [1 ]
Maria Lucia G Ferraz [1 ]
机构
[1] Division of Gastroenterology,Hepatology Section,Federal University of Sao Paulo,Sao Paulo,SP 04023-900,Brazil
关键词
Hepatitis C virus; Chronic kidney disease; End-stage renal disease; Hemodialysis; Kidney transplantation; Diagnosis; Conservative management; Therapy;
D O I
暂无
中图分类号
R692 [肾疾病]; R512.63 [];
学科分类号
1002 ; 100210 ; 100401 ;
摘要
Hepatitis C virus(HCV) infection is highly prevalent among chronic kidney disease(CKD) subjects under hemodialysis and in kidney transplantation(KT) recipients, being an important cause of morbidity and mortality in these patients. The vast majority of HCV chronic infections in the hemodialysis setting are currently attributable to nosocomial transmission. Acute and chronic hepatitis C exhibits distinct clinical and laboratorial features, which can impact on managementand treatment decisions. In hemodialysis subjects, acute infections are usually asymptomatic and anicteric; since spontaneous viral clearance is very uncommon in this context, acute infections should be treated as soon as possible. In KT recipients, the occurrence of acute hepatitis C can have a more severe course, with a rapid progression of liver fibrosis. In these patients, it is recommended to use pegylated interferon(PEG-IFN) in combination with ribavirin, with doses adjusted according to estimated glomerular filtration rate. There is no evidence suggesting that chronic hepatitis C exhibits a more aggressive course in CKD subjects under conservative management. In these subjects, indication of treatment with PEG-IFN plus ribavirin relies on the CKD stage, rate of progression of renal dysfunction and the possibility of a preemptive transplant. HCV infection has been associated with both liver disease-related deaths and cardiovascular mortality in hemodialysis patients. Among those individuals, low HCV viral loads and the phenomenon of intermittent HCV viremia are often observed, and sequential HCV RNA monitoring is needed. Despite the poor tolerability and suboptimal efficacy of antiviral therapy in CKD patients, many patients can achieve sustained virological response, which improve patient and graft outcomes. Hepatitis C eradication before KT theoretically improves survival and reduces the occurrence of chronic graft nephropathy, de novo glomerulonephritis and post-transplant diabetes mellitus.
引用
收藏
页码:408 / 422
页数:15
相关论文
共 50 条
  • [41] Management of patients with chronic hepatitis C infection
    Herrine, SK
    Rossi, S
    Navarro, VJ
    [J]. CLINICAL AND EXPERIMENTAL MEDICINE, 2006, 6 (01) : 20 - 26
  • [42] Management of the Kidney Transplant Patient with Chronic Hepatitis C Infection
    Tang, Ignatius Y. S.
    Walzer, Natasha
    Aggarwal, Nidhi
    Tzvetanov, Ivo
    Cotler, Scott
    Benedetti, Enrico
    [J]. INTERNATIONAL JOURNAL OF NEPHROLOGY, 2011, 2011
  • [43] Incidence of hepatitis C virus infection in patients with chronic kidney disease on conservative therapy
    Cavoli, Gioacchino Li
    Ferrantelli, Angelo
    Bono, Luisa
    Tortorici, Calogera
    Giammarresi, Carlo
    Zagarrigo, Carmela
    Schillaci, Onofrio
    Tralongo, Angelo
    Soresi, Maurizio
    Rotolo, Ugo
    [J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2011, 15 (08) : E514 - E516
  • [44] Safety and efficacy of direct-acting antivirals for chronic hepatitis C in patients with chronic kidney disease
    Elena Laura Iliescu
    Adriana Mercan-Stanciu
    Letitia Toma
    [J]. BMC Nephrology, 21
  • [45] Safety and effectiveness of direct-acting antivirals in patients with chronic hepatitis C and chronic kidney disease
    Ryu, Ji Eun
    Song, Myeong Jun
    Kim, Seok-Hwan
    Kwon, Jung Hyun
    Yoo, Sun Hong
    Nam, Soon Woo
    Nam, Hee Chul
    Kim, Hee Yeon
    Kim, Chang Wook
    Yang, Hyun
    Bae, Si Hyun
    Song, Do Seon
    Chang, U. Im
    Yang, Jin Mo
    Lee, Sung Won
    Lee, Hae Lim
    Lee, Soon Kyu
    Sung, Pil Soo
    Jang, Jeong Won
    Choi, Jong Young
    Yoon, Seung Kew
    [J]. KOREAN JOURNAL OF INTERNAL MEDICINE, 2022, 37 (05): : 958 - 968
  • [46] Safety and efficacy of direct-acting antivirals for chronic hepatitis C in patients with chronic kidney disease
    Iliescu, Elena Laura
    Mercan-Stanciu, Adriana
    Toma, Letitia
    [J]. BMC NEPHROLOGY, 2020, 21 (01)
  • [47] Usefulness of combination therapy with Daclatasvir plus Asunaprevir in chronic hepatitis C patients with chronic kidney disease
    Morisawa, Norihiko
    Koshima, Yohei
    Satoh, Jun-ichi
    Maruyama, Yukio
    Kuriyama, Satoru
    Yokoo, Takashi
    Amemiya, Morimasa
    [J]. CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2017, 21 (05) : 818 - 824
  • [48] Daclatasvir and asunaprevir for genotype 1b chronic hepatitis C patients with chronic kidney disease
    Kondo, Chisa
    Atsukawa, Masanori
    Tsubota, Akihito
    Shimada, Noritomo
    Abe, Hiroshi
    Asano, Toru
    Yoshizawa, Kai
    Okubo, Tomomi
    Chuganji, Yoshimichi
    Aizawa, Yoshio
    Iio, Etsuko
    Tanaka, Yasuhito
    Iwakiri, Katsuhiko
    [J]. HEPATOLOGY RESEARCH, 2017, 47 (11) : 1165 - 1173
  • [49] Usefulness of combination therapy with Daclatasvir plus Asunaprevir in chronic hepatitis C patients with chronic kidney disease
    Norihiko Morisawa
    Yohei Koshima
    Jun-ichi Satoh
    Yukio Maruyama
    Satoru Kuriyama
    Takashi Yokoo
    Morimasa Amemiya
    [J]. Clinical and Experimental Nephrology, 2017, 21 : 818 - 824
  • [50] Hypertension management in patients with chronic kidney disease
    Biff F. Palmer
    [J]. Current Hypertension Reports, 2008, 10 : 367 - 373